Shares drop after management announces the pricing terms of a recently announced secondary offering. Vascular Biogenics announced that it is raising $18.75 million from the sale of 2.5 million shares ...

If you want to know who really controls Vascular Biogenics Ltd. (NASDAQ:VBLT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, ...

Vascular Biogenics Ltd. (NASDAQ:VBLT) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking decline over three years. To ...

In the annals of botched IPOs, there's the BATS disaster, and there's Facebook's notorious debut, but the train wreck that is Vascular Biogenics' IPO stands alone. The company priced its IPO on Nasdaq ...

Aleph Farms said it has acquired a manufacturing facility in Modi'in, Israel, and certain related assets from VBL Therapeutics (NASDAQ:VBLT). Aleph — which grows cultivated steaks from cells isolated ...

It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through ...

Vascular Biogenics Ltd (NASDAQ:VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet ...

The market expects Vascular Biogenics (VBLT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2021. This widely-known ...